Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7646
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Jacksonville, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 817–828 of 7,646 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Completed No phase listed Observational

Peri-Intubation Adverse Airway Events in Critically Ill Patients With Morbid and Super Obesity

NCT07297420
View directory record Official record
Conditions
Obesity, Airway Complication of Anesthesia, Intubation; Difficult or Failed
Interventions
endotracheal intubation
Procedure
Lead sponsor
Zeliha Alicikus
Government
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Recruiting Phase 2 Interventional

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
ABBV-CLS-628, Placebo
Drug
Lead sponsor
Calico Life Sciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Recruiting No phase listed Observational

The Objective of the Protocol is to Generate Real World Evidence (RWE) Supporting the Safety, Performance, and Health Economics of Using the Regulatory Approved and Commercially Available EARP Interbody System Used During Lumbar Interbody Fusion (LIF) Procedures With the EARP Nerve Cuff Electrode

NCT07020000
View directory record Official record
Conditions
Transforaminal Lumbar Interbody Fusion Surgery
Interventions
Device: Nerve Cuff and Retractor System
Device
Lead sponsor
Retropsoas Technologies, LLC
Industry
Eligibility
22 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Jacksonville, Florida • St Louis, Missouri • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

NCT06585462
View directory record Official record
Conditions
Cardiometabolic Disease
Interventions
AMG 513, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
13
States / cities
Anaheim, California • Lake Forest, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Not yet recruiting Phase 3 Interventional

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100
View directory record Official record
Conditions
Cardiovascular Risk, Obesity
Interventions
Zenagamtide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
8,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
155
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Recruiting Phase 2 Interventional

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arlocabtagene Autoleucel
Biological
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

NCT05462145
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions
Globe Pulsed Field System
Device
Lead sponsor
Kardium Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Completed Phase 3 Interventional

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Completed Phase 3 Interventional Results available

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

NCT02003209
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
Drug · Other · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
731
States / cities
Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Active, not recruiting Phase 2 Interventional Results available

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

NCT03581292
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions
Radiation Therapy, Temozolomide, Veliparib
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 25 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
145
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
ONO-2808, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

NCT03504644
View directory record Official record
Conditions
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Positron Emission Tomography, Venetoclax, Vincristine Liposomal, Vincristine Sulfate
Procedure · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
163
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 8:10 AM EST